Advanced in Virilizing Ovarian Tumor

Dr. Nonyem A. Onujiogu

Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Beacon Medical Group Inc
100 Navarre Pl, 4470 Bmg Womens Surgical Gyn/onc At Mrcc, 
South Bend, IN 
 (287.9 mi)
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Advanced in Virilizing Ovarian Tumor
Beacon Medical Group Inc
100 Navarre Pl, 4470 Bmg Womens Surgical Gyn/onc At Mrcc, 
South Bend, IN 
 (287.9 mi)
OverviewInsuranceLocationsClinical Research

Overview

Nonyem Onujiogu is a Gynecologic Oncologist and an Oncologist in South Bend, Indiana. Dr. Onujiogu and is rated as an Advanced provider by MediFind in the treatment of Virilizing Ovarian Tumor. Her top areas of expertise are Malignant Mixed Mullerian Tumor, Cervical Cancer, Neuroendocrine Carcinoma of the Cervix, Salpingo-Oophorectomy, and Oophorectomy. Dr. Onujiogu is currently accepting new patients.

Her clinical research consists of co-authoring 2 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Gynecologic Oncology
Oncology
Obstetrics and Gynecology
Licenses
Obstetrics & Gynecology in IN
Hospital Affiliations
Lakeland Hospital, St Joseph
Elkhart General Hospital
Memorial Hospital Of South Bend
Languages Spoken
English
Gender
Female

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Anthem
  •  CareSource
  •  Humana

Locations

BEACON MEDICAL GROUP INC
100 Navarre Pl, 4470 Bmg Womens Surgical Gyn/onc At Mrcc, South Bend, IN 46601

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
Enrollment Status: Recruiting
Publish Date: May 02, 2024
Intervention Type: Drug, Procedure
Study Drugs: Carboplatin, Letrozole, Paclitaxel
Study Phase: Phase 3
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
Enrollment Status: Active_not_recruiting
Publish Date: July 16, 2024
Intervention Type: Procedure, Drug, Other
Study Drugs: Cediranib, Cediranib Maleate, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan, Topotecan Hydrochloride
Study Phase: Phase 2/Phase 3
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 08, 2023
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Atezolizumab, Bevacizumab, Pegylated liposomal doxorubicin hydrochloride
Study Phase: Phase 2/Phase 3
A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
Enrollment Status: Active_not_recruiting
Publish Date: March 29, 2023
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
A Phase III Randomized Trial of Pulse Actinomycin-D Versus Multi-day Methotrexate for the Treatment of Low-Risk Gestational Trophoblastic Neoplasia
A Phase III Randomized Trial of Pulse Actinomycin-D Versus Multi-day Methotrexate for the Treatment of Low-Risk Gestational Trophoblastic Neoplasia
Enrollment Status: Completed
Publish Date: August 12, 2022
Intervention Type: Other, Drug, Biological
Study Drugs: Dactinomycin, Leucovorin Calcium, Methotrexate
Study Phase: Phase 3
Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy (NCT #01101451)
Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy (NCT #01101451)
Enrollment Status: Unknown
Publish Date: May 24, 2022
Intervention Type: Other, Radiation, Drug
Study Drug: Cisplatin
Study Phase: Phase 3
View 5 Less Clinical Trials

2 Total Publications

DcR3 binds to ovarian cancer via heparan sulfate proteoglycans and modulates tumor cells response to platinum with corresponding alteration in the expression of BRCA1.
DcR3 binds to ovarian cancer via heparan sulfate proteoglycans and modulates tumor cells response to platinum with corresponding alteration in the expression of BRCA1.
Journal: BMC cancer
Published: February 04, 2012
Similar Doctors
Distinguished in Virilizing Ovarian Tumor
Dr. Julia A. Chapman
Gynecologic Oncology | Obstetrics and Gynecology | Oncology
Distinguished in Virilizing Ovarian Tumor
Dr. Julia A. Chapman
Gynecologic Oncology | Obstetrics and Gynecology | Oncology

Beacon Medical Group Inc

615 N Michigan St, Fl 5, 
South Bend, IN 
 (0.1 mi)
574-647-7275
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Julia Chapman is a Gynecologic Oncologist and an Obstetrics and Gynecologist in South Bend, Indiana. Dr. Chapman and is rated as a Distinguished provider by MediFind in the treatment of Virilizing Ovarian Tumor. Her top areas of expertise are Ovarian Cancer, Endometrial Cancer, Malignant Mixed Mullerian Tumor, Oophorectomy, and Salpingo-Oophorectomy. Dr. Chapman is currently accepting new patients.

Distinguished in Virilizing Ovarian Tumor
Dr. Anna V. Hoekstra
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Distinguished in Virilizing Ovarian Tumor
Dr. Anna V. Hoekstra
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

West Michigan Cancer Center

200 N Park St, 
Kalamazoo, MI 
 (54.2 mi)
269-373-7453
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Anna Hoekstra is a Gynecologic Oncologist and an Oncologist in Kalamazoo, Michigan. Dr. Hoekstra and is rated as a Distinguished provider by MediFind in the treatment of Virilizing Ovarian Tumor. Her top areas of expertise are Endometrial Cancer, Malignant Mixed Mullerian Tumor, Endometrial Stromal Sarcoma, Oophorectomy, and Hysterectomy. Dr. Hoekstra is currently accepting new patients.

Advanced in Virilizing Ovarian Tumor
Dr. Latoya J. Perry
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Advanced in Virilizing Ovarian Tumor
Dr. Latoya J. Perry
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

Beacon Medical Group Inc

100 Navarre Pl, 4470 Bmg Womens Surgical Gyn/onc At Mrcc, 
South Bend, IN 
574-647-4230
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Latoya Perry is a Gynecologic Oncologist and an Oncologist in South Bend, Indiana. Dr. Perry and is rated as an Advanced provider by MediFind in the treatment of Virilizing Ovarian Tumor. Her top areas of expertise are Endometrial Cancer, Vulvar Cancer, Ovarian Cancer, Lymphadenectomy, and Hysterectomy. Dr. Perry is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile